Clinical trials: Heart Infarction
Left Ventricular Dysfunction Post Myocardial Infarction
Patient's Management Receiving Eplerenone Therapy
On a population of patients followed by an office-based cardiologist and treated with eplerenone, the objectives of the survey are: To describe the characteristics of the population treated.
- Trial name
- PERGAME (NCT01440049)
- Testing
- Prospective Observational
- Volunteers
- 160 people
- Sponsor
- Pfizer
Stem Cell Transplantation
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional…
- Trial name
- NCT01087996
- Testing
- Auto-hMSCs, Allo-hMSCs
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Miami
Myocardial Infarction
Genetic Variation in Platelet Aggregation
The aim of the study is to test whether genetic variation in the alpha 2A adrenergic receptor affects diurnal variation in platelet aggregation.
- Trial name
- NCT01576536
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Myocardial Infarction, Comorbidity
Web-Enhanced Guideline Implementation for Post MI CBOC Patients
To assist busy primary care clinicians in VA Community Based Outpatient Clinics (CBOCs) in managing complex patients by providing a single, interactive, and personalized source of information regarding applicable guidelines for…
- Trial name
- VA MI Plus (NCT00126750)
- Testing
- VA MI Plus Interactive
- Where
- 41 sites in United States, Puerto Rico
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Myocardial Infarction
Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Most of the previous data regarding the efficacy of the everolimus-eluting stent (EES) was derived from studies comparing EES with bare metal stent (BMS) or EES with paclitaxel-eluting (PES).
- Trial name
- EVERZOTA (NCT01347554)
- Testing
- Everolimus eluting stent, Zotarolimus eluting stent
- Where
- South Korea
- Volunteers
- 461 people
- Sponsor
- Yonsei University
Smoking Cessation, Acute Coronary Syndrome
Post Acute Coronary Event Smoking Study
Smoking and depressed mood are both predictive of mortality following Acute Coronary Syndrome. However, to date, no counseling treatment has been designed to target smoking cessation and manage mood in this population.
- Trial name
- PACES (NCT01964898)
- Testing
- Behavioral Activation (BA), Standard Smoking Cessation Counseling, Nicotine patch
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- The Miriam Hospital
Coronary Artery Disease
The Medtronic RESOLUTE US Clinical Trial
The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter…
- Trial name
- R-US (NCT00726453)
- Testing
- Resolute Zotarolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 1,516 people
- Sponsor
- Medtronic Vascular
Acute Myocardial Infarction
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug.
- Trial name
- NCT03487445
- Testing
- Selatogrel 8 mg, Selatogrel 16 mg
- Where
- 6 sites in Belgium, Israel and 1 more
- Volunteers
- 48 people
- Sponsor
- Viatris Innovation GmbH
Coronary Artery Disease
ST Segment Detection Study
The purpose of ST Detect study is to evaluate whether naturally occurring spontaneous coronary events and exercise induced cardiac ischemia, give rise to detectable changes on intracardiac electrogram (EGM) signals in patients…
- Trial name
- ST Detect (NCT00930969)
- Testing
- ICD
- Where
- 25 sites in United States, Austria and 5 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Infarction, Myocardial
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Multinational, multicentre, randomised, prospective, open, parallel group study directly comparing two glycoprotein-IIb/IIIa inhibitors, abciximab and eptifibatide, added early to standard treatment before primary PCI of STEMI…
- Trial name
- NCT00426751
- Testing
- Abciximab, Eptifibatide
- Where
- 24 sites in France, Germany
- Volunteers
- 429 people
- Sponsor
- GlaxoSmithKline
Chest Pain, Coronary Artery Disease
ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study
The first aim of this trial is to assess the long-term prognostic value of Omega-3 index, which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane…
- Conditions
- Chest Pain, Coronary Artery Disease, Unstable Angina Pectoris, Myocardial Infarction
- Trial name
- ARRA-RACS (NCT01377402)
- Where
- 10 sites in Argentina, Norway
- Volunteers
- 982 people
- Sponsor
- Helse Stavanger HF
ST-segment Elevation Myocardial Infarction
Distal Protection Device in ST-elevation Myocardial Infarction (STEMI)
The investigators examined the mechanism underlying the lack of benefit from distal protection and thrombus aspiration (DP-TA) in 126 patients with ST-elevation Myocardial Infarction (STEMI) in a prospective, randomized trial.
- Trial name
- NCT01384019
- Testing
- distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.)), c-PCI
- Where
- South Korea
- Volunteers
- 126 people
- Sponsor
- Seoul National University Bundang Hospital
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Myocardial Infarction
A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction
The purpose of this study is to evaluate whether the mobile-phone based patient support has an impact on the adherence and persistence of ticagrelor treatment or on lifestyle changes that will have a positive impact on the…
- Trial name
- SUPPORT (NCT01874262)
- Testing
- Mobile-phone based patient support, e-diary
- Where
- 13 sites in Sweden
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Myocardial Infarction
STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction
In patients ≥ 60yrs with acute ST-elevation myocardial infarction randomised within 3 hours of onset of symptoms the efficacy and safety of a strategy of early fibrinolytic treatment with half-dose tenecteplase and additional…
- Trial name
- STREAM-2 (NCT02777580)
- Testing
- Tenecteplase, Clopidogrel, Coronary angiography
- Where
- 50 sites in Australia, Brazil and 8 more
- Volunteers
- 609 people
- Sponsor
- KU Leuven
Acute Myocardial Infarction
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.
- Trial name
- EMMY (NCT03087773)
- Testing
- Empagliflozin 10 mg
- Where
- 11 sites in Austria
- Volunteers
- 476 people
- Sponsor
- Medical University of Graz
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Venous Thromboembolism
Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
Warfarin is very effective for the prevention of blood clots (thrombosis). A test of coagulation, the prothrombin time (PT) is used to monitor the effect.
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction
- Trial name
- FORESPEAK-0 (NCT00814177)
- Testing
- warfarin
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Hamilton Health Sciences Corporation
Myocardial Infarction, Myocardial Ischemia
Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time
The specific aim of this study is to assess whether a device approved by the FDA to measure pulse oximetry can accurately estimate cardiac output.
- Trial name
- esCCO (NCT01877941)
- Testing
- Pulmonary Artery Catheter (PAC), Endotracheal Cardiac Output Monitor (ECOM), Estimated Continuous Cardiac Output (esCCO)
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of California, San Francisco
Multi Vessel Coronary Artery Disease, STEMI
Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI
The purpose of this study is to assess whether the Index of Microcirculatory Resistance (IMR) can be considered a prognostic predictor for the occurrence of events at one year of follow up after primary Percutaneous Coronary…
- Trial name
- AMICRO (NCT02325973)
- Testing
- PressureWire Certus guidewire
- Where
- 14 sites in Italy
- Volunteers
- 242 people
- Sponsor
- Abbott Medical Devices